触发性反应与延长释放每晚一次的氧酸盐:来自第三阶段REST-ON临床试验的特设后响应者分析
Michael J Thorpy1, Clete A Kushida2, Richard Bogan3
1Albert Einstein College of Medicine, New York, NY, USA.
Sleep medicine: X
|April 11, 2024
概括
每晚一次的氧酸盐 (ON-SXB) 在1型麻醉症患者中显著减少了触角症发作. 高剂量的ON-SXB导致大量的减少,有些人完全消除了触感.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 临床药理学 临床药理学
背景情况:
- 每晚一次的氧酸 (ON-SXB) 是氧酸的延长释放配方.
- 在REST-ON 3期临床试验中,ON-SXB.显示了随着ON-SXB.发生的触发性情节的显著减少.
- 本分析的重点是1型麻醉症 (NT1) 的参与者.
研究的目的:
- 分析用ON-SXB.治疗NT1的参与者中触发性情节的变化.
- 评估ON-SXB在减少NT1患者每周发生的触角症发作方面的疗效.
主要方法:
- 年龄≥16岁的参与者接受了升级剂量的ON-SXB或安慰剂.
- 该研究评估了NT1患者的百分比,他们每周减少了≥25%,≥50%,≥75%和100%的触感症发作.
- 费舍尔精确测试用于ON-SXB和安慰剂组之间的统计比较.
主要成果:
- 与所有测试剂量的安慰剂相比,接受ON-SXB的NT1参与者在每周的触角症发作中显著减少,与安慰剂相比.
- 在最高的ON-SXB剂量 (7.5g和9g) 中,大约50%的参与者经历了≥50%的减少,约10%的参与者实现了100%的减少.
- 显著的减少 (P <0.05) 早在第1周 (4.5克) 已被观察到,并持续到第13周 (9克).
结论:
- 在患有NT1的参与者中,ON-SXB证明了每周触角症发作的显著和剂量依赖的减少.
- 在接受更高剂量的ON-SXB治疗的参与者中,显著比例的参与者实现了大量的彻底消除 kataplexy.
- ON-SXB是一种有效的治疗选择,用于控制1型麻醉症的触觉障碍症.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
176
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
176
Narcolepsy
102
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
102
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
288
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
288
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Electroconvulsive Therapy
39
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
39
Antiepileptic Drugs: Sodium Channel Blockers
522
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
522


